Role of hypoxia-inducible factor (HIF)-1 alpha-versus HIF-2 alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway
MetadataShow full item record
Overexpression of hypoxia-inducible factors (HIF), HIF-1 alpha and HIF-2 alpha, leads to the up-regulation of genes involved in proliferation, angiogenesis, and glucose metabolism and is associated with tumor progression in several cancers. However, the contribution of HIF-1 alpha versus HIF-2 alpha to vascular endothelial growth factor (VEGF) expression and other HIF-regulated target genes under different conditions is unclear. To address this, we used small interfering RNA (siRNA) techniques to knockdown HIF-1 alpha and/or HIF-2 alpha expression in response to hypoxia, insulin-like growth factor (IGF)-I, or renal carcinoma cells expressing constitutively high basal levels of HIF-1 alpha and/or HIF-2 alpha due to loss of von Hippel-Lindau (VHL) function. We found that HIF-1 alpha primarily regulates transcriptional activation of VEGF in response to hypoxia and IGF-I compared with HIF-2 alpha in MCF-7 cells. We also observed a reciprocal relationship between HIF-1 alpha and HIF-2a expression in hypoxia in these cells: HIF-2 alpha siRNA enhanced HIF-1 alpha-mediated VEGF expression in MCF-7 cells in response to hypoxia, which could be completely blocked by cotransfection with HIF-1 alpha siRNA. In contrast, in renal carcinoma cells that constitutively express HIF-1 alpha and HIF-2 alpha due to loss of VHL function, we found that high basal VEGF, glucose transporter-1, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 expression was predominantly dependent on HIF-2 alpha. Finally, we showed that a newly identified small-molecule inhibitor of HIF-1, NSC-134754, is also able to significantly decrease HIF-2 alpha protein expression and HIF-2 alpha-regulated VEGF levels in renal carcinoma cells. Our data have important implications for how we target the HIF pathway therapeutically.
Version of record
License start date
CANCER RESEARCH, 2006, 66 pp. 6264 - 6270
AMER ASSOC CANCER RESEARCH